A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
Recruiting now Phase 2 NCT07012395
Run by Spyre Therapeutics, Inc. · for 18 and older · All sexes
What this study is about
This is a Phase 2, multicenter, proof-of-concept platform study in adult participants with moderately to severely active ulcerative colitis (UC). The primary goal of the study is to assess the efficacy and safety of multiple interventions following intravenous (IV) induction and subcutaneous (SC) maintenance treatment.
Who can join (things the study team will check)
✅ You may be able to join if…
- Diagnosis of UC for ≥3 months before Day 1, confirmed by endoscopy and histology either previously or during Screening
- Active UC with disease extent of ≥15 cm from the anal verge, as confirmed by Screening endoscopy (up to approximately 15% allowed to have only proctitis)
- Moderately to severely active disease as defined by a modified Mayo score of 5-9, rectal bleeding subscore of ≥1, and Mayo endoscopic subscore ≥2
🚫 You may not be able to join if…
- Current diagnosis of Crohn's disease or Inflammatory Bowel Disease (IBD)-Undefined
- Confirmed or suspected fulminant colitis, toxic megacolon, bowel perforation and/or other conditions that will likely require surgery during induction
- Failed 4 or more approved or investigational advanced therapy classes
Where this trial is running
- Site 024, Canoga Park, California, United States
- Site 023, La Jolla, California, United States
- Site 012, Lancaster, California, United States
- Site 033, Colorado Springs, Colorado, United States
- Site 007, Kissimmee, Florida, United States
- 029, Miami, Florida, United States
- Site 006, Kansas City, Kansas, United States
- Site 030, Louisville, Kentucky, United States
- Site 035, Marrero, Louisiana, United States
- Site 011, Glen Burnie, Maryland, United States
- Site 003, Boston, Massachusetts, United States
- Site 028, Rochester, Minnesota, United States
+ 231 more sites.
Who to contact
SKYLINE-UC Trial Center · 1-650-402-4238 · info@skyline-uc.com
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT07012395.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.
Beacon is an information tool, not medical advice. Whether a trial is right for you is a decision for you, your doctor, and the study team. Trial details come from the official registry, ClinicalTrials.gov, and may change — always confirm with the study team. Beacon collects no data about you: this page has no cookies, no accounts, and no tracking.